Acid Neutralizers Segment Held Largest Share of Gastrointestinal Drugs Market in 2019
According to our new market research study on “South and Central America Gastrointestinal Drugs Market to 2027 – Regional Analysis and Forecast – by Drug Class, Route of Administration, Application, and Distribution Channel” the market is expected to reach US$ 5,632.72 million by 2027 from US$ 4,160.28 million in 2019; it is estimated to grow at a CAGR of 4.0% from 2020 to 2027. The report provides trends prevailing in the South and Central America gastrointestinal drugs market and the factors driving the market growth along with those hindering it.
In 2019, the acid neutralizers segment accounted for the highest share of the market. However, the biologics segment is expected to be the fastest-growing during the forecast period. The CAGR of the biologics segment has the highest CAGR in the forecast period. The growth of the segment is attributed to growing product development and increasing product launches in the market.
The growth of the South and Central America Gastrointestinal Drugs market is mainly attributed to rising prevalence of gastrointestinal (GI) diseases, and increase in development of biologics. However, side effects associated with the drugs will restrict the market growth.
Celltrion Healthcare Co.,Ltd; GlaxoSmithKline plc; Johnson and Johnson Services, Inc.; AstraZeneca; and Takeda Pharmaceutical Company Limited are among the leading companies operating in the South and Central America Gastrointestinal Drugs market.
South and Central America Gastrointestinal Drugs Market, By Country, 2019 (%)
South & Central America Gastrointestinal Drugs Market to Grow at a CAGR of 4.0% to reach US$ 5,632.72 Million from 2020 to 2027
Download Free Sample
South & Central America Gastrointestinal Drugs Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Drug Class (Acid Neutralizers, Antidiarrheal and Laxatives, Anti-Inflammatory Drugs, Antiemetic and Antinauseants, Biologics, and Others); Route of Administration (Oral, and Parenteral); Application (Inflammatory Ulcerative Colitis, Crohn's Disease, Irritable Bowel Syndrome, Gastroenteritis, Celiac Disease, and Others); and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Country
South & Central America Gastrointestinal Drugs Market to Grow at a CAGR of 4.0% to reach US$ 5,632.72 Million from 2020 to 2027
Download Free SampleSouth & Central America Gastrointestinal Drugs Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Drug Class (Acid Neutralizers, Antidiarrheal and Laxatives, Anti-Inflammatory Drugs, Antiemetic and Antinauseants, Biologics, and Others); Route of Administration (Oral, and Parenteral); Application (Inflammatory Ulcerative Colitis, Crohn's Disease, Irritable Bowel Syndrome, Gastroenteritis, Celiac Disease, and Others); and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Country
The Report Segments South and Central America Gastrointestinal Drugs Market as Follows:
South and Central America Gastrointestinal Drugs Market – By Drug Class
- Acid Neutralizers
- Antidiarrheal and Laxatives
- Anti-Inflammatory Drugs
- Antiemetic and Antinauseants
- Biologics
- Others
South and Central America Gastrointestinal Drugs Market – By Route of Administration
- Oral
- Parenteral
South and Central America Gastrointestinal Drugs Market – By Application
- Inflammatory Ulcerative Colitis
- Crohn's Disease
- Irritable Bowel Syndrome
- Gastroenteritis
- Celiac Disease
- Others
South and Central America Gastrointestinal Drugs Market – By Country
- South and Central America
- Brazil
- Argentina
- Rest of South and Central America